The Antiplaque and Antigingivitis OTC Monograph: Science, Regulation, and the Future of Gum Health

Gum health is a vital, yet often overlooked, component of overall well-being. While much public attention is given to cavity prevention, the fight against plaque and gingivitis is just as crucial. In the United States, the regulation of over-the-counter (OTC) products that claim to reduce dental plaque and prevent or treat gingivitis is governed by the FDA’s Antiplaque and Antigingivitis Monograph. This regulatory framework is the backbone of consumer trust in products like therapeutic mouthwashes and select toothpastes. Below, we'll discuss the origins, structure, and current status of the antiplaque and antigingivitis monograph, how it shapes the oral care industry, and what it means for the future of gum health.

What Is the Antiplaque and Antigingivitis OTC Monograph?

The antiplaque and antigingivitis monograph is a set of FDA regulations that governs the formulation, labeling, and marketing of nonprescription oral care products claiming to reduce dental plaque and/or gingivitis. Like other OTC monographs, it defines which active ingredients are allowed, their concentrations, acceptable dosage forms, and the claims that can be made on product labels. Products meeting all these criteria are considered “generally recognized as safe and effective” (GRASE) and can be sold without a New Drug Application (NDA).

This system is intended to streamline access to proven therapies for consumers while ensuring safety and efficacy. It also provides manufacturers with a clear, predictable pathway to market for products that address two of the most common oral health problems: plaque accumulation and gum inflammation.

The History and Development of the Antiplaque/Antigingivitis Monograph

The Need for Regulation

By the late 20th century, scientific research had established a clear link between dental plaque, gingivitis, and more severe forms of gum disease. As new oral care products with antiplaque and antigingivitis claims began to appear, the FDA recognized the need for a regulatory framework to ensure these products were both safe and effective.

The OTC Drug Review Process

The process for developing the antiplaque and antigingivitis monograph followed the standard FDA OTC drug review pathway:

1. Advance Notice of Proposed Rulemaking (ANPR): The FDA began by soliciting data and public comments on ingredients and claims for antiplaque and antigingivitis products.

2. Tentative Final Monograph (TFM): After reviewing the evidence, the FDA issued a TFM, proposing which ingredients and claims would be considered GRASE.

3. Ongoing Review: As of 2025, the antiplaque and antigingivitis monograph remains in a tentative status. Products that comply with the TFM are generally allowed on the market while the FDA continues to review new data and public input.

The monograph’s development has involved input from dental professionals, manufacturers, scientific experts, and consumer advocates, ensuring a robust and evidence-based regulatory framework.

What Does the Monograph Cover?

Scope and Applicability

The antiplaque and antigingivitis monograph applies to all OTC oral care products that claim to reduce or control dental plaque or gingivitis. This includes:

• Mouthwashes (rinses)

• Toothpastes (dentifrices)

• Gels

• Other topical oral care products

It does not apply to products intended solely for cosmetic purposes or to prescription-only therapies.

Approved Active Ingredients

A core function of the monograph is to specify which active ingredients are permitted for antiplaque and antigingivitis claims. Only those with substantial evidence of safety and efficacy are included.

Stannous Fluoride

Stannous fluoride is unique in that it is recognized for both anticaries and antigingivitis/antiplaque effects. It is allowed in toothpastes at specified concentrations, and its dual action makes it a popular choice for products targeting both cavities and gum health.

Cetylpyridinium Chloride (CPC)

CPC is a quaternary ammonium compound with proven efficacy in reducing plaque and gingivitis. It is commonly found in mouthwashes and is permitted under the monograph at specific concentrations.

Essential Oils

Certain fixed combinations of essential oils (including eucalyptol, menthol, methyl salicylate, and thymol) are allowed as active ingredients in mouth rinses. These combinations have demonstrated effectiveness in reducing plaque and gingivitis, particularly in long-term clinical studies.

Other Ingredients

Other ingredients, such as zinc citrate, have been considered, but only those with sufficient supporting data and a history of safe use are included in the monograph. Ingredients previously used but later found to be problematic, such as triclosan, have been removed from the U.S. market due to safety concerns.

Dosage Forms and Combinations

The monograph allows a variety of dosage forms, provided the active ingredient is effective in that form. These include:

• Mouthwashes (with or without alcohol)

• Toothpastes

• Gels

It also permits rational combinations of antiplaque/antigingivitis ingredients with other oral health actives, such as fluoride (for anticaries) and tooth desensitizers, as long as each ingredient is present at an approved concentration and the product meets all labeling and performance standards.

Labeling Requirements

Labeling is a critical part of the monograph, designed to ensure consumers are informed about the product’s intended use, directions, and potential risks.

Indications and Claims

Permitted claims are strictly defined. For example, products may state that they “help control,” “reduce,” “prevent,” or “remove” plaque that leads to gingivitis. For gingivitis, the labeling can include terms like “control,” “reduce,” or “prevent,” reflecting the product’s demonstrated benefits.

The monograph’s labeling provisions are intended to communicate the full range of benefits to consumers. For example, a product that both reduces plaque and gingivitis can be labeled for both indications, rather than being limited to a single claim.

Warnings

The monograph specifies required warnings, such as:

• “Stop use and ask a dentist if gingivitis, bleeding, or redness persists for more than 2 weeks.”

• “If you have painful or swollen gums, pus from the gum line, loose teeth, or increasing spacing between the teeth, these may be signs of periodontitis, a serious form of gum disease.”

There has been ongoing debate about the wording and placement of these warnings, with some stakeholders advocating for language that encourages continued product use while also advising professional consultation when necessary.

Directions for Use

Directions must be clear and age-appropriate, specifying how much to use, how often, and for how long. For mouthwashes, instructions typically include “do not swallow” and supervision for children as appropriate.

Drug Facts Panel

Like all OTC drugs, antiplaque/antigingivitis products must include a standardized Drug Facts panel listing active and inactive ingredients, uses, warnings, directions, and other required information.

Testing and Quality Standards

To ensure safety and efficacy, the monograph mandates specific testing for final formulations:

• Efficacy Testing: Products must demonstrate statistically significant superiority over a negative control and noninferiority to a reference standard in clinical trials. For new dosage forms, at least one six-month, single-site, negative-controlled clinical study is generally required.

• Stability and Purity: Manufacturers must ensure that the active ingredient remains effective and stable throughout the product’s shelf life.

• Microbiological Testing: Products must be free from harmful microorganisms and meet FDA standards for purity.

These requirements ensure that products deliver the promised benefits and remain safe for daily use.

Combination Products

The monograph explicitly allows for rational combinations of antiplaque/antigingivitis ingredients with other oral health actives, such as:

• Anticaries agents (e.g., fluoride)

• Tooth desensitizers (e.g., potassium nitrate)

• Both anticaries and desensitizer ingredients

Such combinations are considered safe and effective as long as each ingredient is present at an approved concentration and the product meets all other monograph requirements.

Mechanisms of Action

The monograph recognizes that different active ingredients may work via different mechanisms. For example:

• Stannous fluoride acts by interfering with bacterial metabolism and inhibiting plaque formation, while also reducing inflammation associated with gingivitis.

• Cetylpyridinium chloride disrupts bacterial cell membranes, reducing the overall bacterial load in the mouth.

• Essential oils have a broad spectrum of antimicrobial effects and can penetrate biofilms, helping to reduce both plaque and gingivitis.

The monograph does not require a single mechanism of action, as long as the product demonstrates clinical efficacy in reducing plaque and/or gingivitis.

The Rulemaking Process: From Proposal to TFM

The antiplaque and antigingivitis monograph has followed the standard FDA rulemaking process:

• Advance Notice of Proposed Rulemaking (ANPR): The FDA solicited data and public comments on ingredients, claims, and safety issues.

• Tentative Final Monograph (TFM): After reviewing the evidence, the FDA issued a TFM, which forms the basis for current regulatory oversight.

• Ongoing Review: The monograph remains in a tentative status, meaning products that comply with the TFM are generally allowed on the market, but the FDA continues to review new data and may update the monograph as needed.

This process ensures that the monograph reflects the best available science and public health priorities.

The Role of Industry and Public Comment

The development and ongoing revision of the antiplaque and antigingivitis monograph has involved extensive input from industry groups, dental professionals, and consumer advocates. Stakeholders have provided data, submitted comments, and participated in advisory panels to ensure that the monograph is both scientifically sound and practical for manufacturers and consumers.

For example, industry groups have advocated for:

• Broader labeling options to reflect the full range of product benefits

• Flexible testing standards that accommodate scientific advances

• Reduced labeling requirements for small or convenience-sized products

The FDA considers these comments as part of its ongoing review and may incorporate them into future updates to the monograph.

Current Status and Future Directions

As of 2025, the antiplaque and antigingivitis monograph remains in a tentative status. Products that comply with the TFM are generally considered GRASE and may remain on the market. The FDA continues to review new scientific data, safety reports, and public comments, and may issue updates or a final monograph in the future.

Recent legislative reforms, such as the CARES Act, have streamlined the process for updating monographs, allowing the FDA to respond more quickly to emerging science and public health needs. This ensures that the monograph system remains flexible and responsive while maintaining high standards for safety and efficacy.

Impact on Public Health

The antiplaque and antigingivitis monograph has had a significant impact on oral health in the United States:

• Increased Access: By allowing safe and effective products to be sold without a prescription, the monograph has made gum disease prevention accessible to millions.

• Consumer Confidence: The monograph ensures that products on the market have been rigorously evaluated for safety and efficacy.

• Reduced Disease Burden: Widespread use of antiplaque and antigingivitis products has contributed to declines in the prevalence and severity of gum disease.

The monograph also supports ongoing innovation in oral care, as manufacturers are encouraged to develop new formulations and combinations within the framework of established safety and efficacy standards.

Challenges and Controversies

Despite its successes, the monograph system faces ongoing challenges:

• Evolving Science: New research may identify additional effective ingredients or novel dosage forms, requiring updates to the monograph.

• Labeling and Consumer Understanding: There is ongoing debate about how best to communicate product benefits and risks, especially for combination products.

• Global Harmonization: Differences between U.S. and international regulations can create challenges for manufacturers seeking to market products globally.

The FDA and stakeholders continue to work together to address these challenges and ensure that the monograph remains relevant and effective.

The Antiplaque and Antigingivitis Monograph as a Pillar of Gum Health

The FDA’s antiplaque and antigingivitis OTC monograph is a cornerstone of oral health regulation in the United States. By establishing clear, evidence-based standards for ingredients, labeling, and testing, it ensures that consumers have access to safe and effective products for preventing and treating gum disease. The monograph’s ongoing evolution reflects the dynamic nature of science and public health, balancing innovation with consumer protection.

Whether you’re a consumer seeking the best mouthwash for healthy gums or a manufacturer developing the next generation of oral care products, the antiplaque and antigingivitis monograph is your assurance of quality, safety, and efficacy. As science advances and public health needs evolve, this regulatory framework will continue to play a vital role in safeguarding the nation’s gum health.

---

Howard Law is a business, regulatory and M&A law firm in the greater Charlotte, North Carolina area, with additional services in M&A advisory and business brokerage. Howard Law is a law firm based in the greater Charlotte, North Carolina area focused on business law, corporate law, regulatory law, mergers & acquisitions, M&A advisor and business brokerage. Handling all business matters from incorporation to acquisition as well as a comprehensive understanding in assisting through mergers and acquisition. The choice of a lawyer is an important decision and should not be based solely on advertisements. The information on this website is for general and informational purposes only and should not be interpreted to indicate a certain result will occur in your specific legal situation. Information on this website is not legal advice and does not create an attorney-client relationship. You should consult an attorney for advice regarding your individual situation. Contacting us does not create an attorney-client relationship. Please do not send any confidential information to us until such time as an attorney-client relationship has been established.